InterCure Ltd
TASE:INCR
Operating Margin
InterCure Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IL |
I
|
InterCure Ltd
TASE:INCR
|
243.8m ILS |
9%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
731.4B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
393.8B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
205.6B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
180.8B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
159.6B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
201.2B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
139.1B USD |
27%
|
InterCure Ltd
Glance View
InterCure Ltd. engages in the business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on InterCure Ltd's most recent financial statements, the company has Operating Margin of 8.9%.
You don't have any saved screeners yet